Table 1
Baseline patient characteristics of the overall cohort and the propensity-score-matched cohort.
| THE TOTAL STUDY COHORT | THE PROPENSITY-SCORE-MATCHED COHORT | |||||
|---|---|---|---|---|---|---|
| DAPT > 1-YEAR(N = 2201) | DAPT = 1-YEAR(N = 1004) | P VALUE | DAPT > 1-YEAR(N = 1000) | DAPT = 1-YEAR(N = 1000) | P VALUE | |
| Demographics | ||||||
| Age (y) | 60.27 ± 10.06 | 58.67 ± 10.24 | <0.001 | 58.83 ± 10.26 | 58.75 ± 10.17 | 0.862 |
| Male | 1658 (75.33) | 759 (75.60) | 0.870 | 766 (76.60) | 755 (75.50) | 0.564 |
| BMI (kg/m2) | 25.94 ± 3.20 | 25.71 ± 3.00 | 0.063 | 25.91 ± 3.28 | 25.70 ± 3.00 | 0.157 |
| Medical history | ||||||
| Prior PCI | 807 (36.67) | 328 (32.67) | 0.028 | 318 (31.80) | 327 (32.70) | 0.667 |
| Prior CABG | 63 (2.86) | 13 (1.29) | 0.007 | 22 (2.20) | 13 (1.30) | 0.125 |
| Prior MI | 188 (8.54) | 57 (5.68) | 0.005 | 64 (6.40) | 57 (5.70) | 0.511 |
| Prior Stroke | 183 (8.31) | 75 (7.47) | 0.415 | 72 (7.20) | 75 (7.50) | 0.797 |
| Risk factors | ||||||
| Hypertension | 1345 (61.11) | 604 (60.16) | 0.610 | 593(59.30) | 603 (60.30) | 0.648 |
| Diabetes | 734 (33.35) | 283 (28.19) | 0.004 | 300 (30.00) | 283 (28.30) | 0.403 |
| Hyperlipidemia | 809 (36.76) | 358 (35.66) | 0.549 | 352 (35.20) | 357 (35.70) | 0.815 |
| Family history of CAD | 99 (4.50) | 38 (3.78) | 0.355 | 30 (3.00) | 38 (3.80) | 0.324 |
| Current smoker | 723 (32.85) | 320 (31.87) | 0.584 | 329 (32.90) | 320 (32.00) | 0.667 |
| Examination | ||||||
| LVEF (%) | 61.96 ± 7.80 | 62.27 ± 7.60 | 0.359 | 62.18 ± 7.84 | 62.26 ± 7.60 | 0.830 |
| WBC (*109/L) | 7.07 ± 1.98 | 7.07 ± 2.06 | 0.985 | 7.21 ± 2.14 | 7.07 ± 2.06 | 0.136 |
| Hemoglobin (g/L) | 140.84 ± 14.90 | 140.93 ± 14.69 | 0.879 | 141.37 ± 14.26 | 140.89 ± 14.70 | 0.467 |
| Crcl (mL/min) | 100.13 ± 30.811 | 101.95 ± 29.68 | 0.136 | 102.40 ± 31.45 | 101.80 ± 29.65 | 0.673 |
| Clinical presentation | ||||||
| STEMI | 326 (14.81) | 142 (14.14) | 0.063 | 131 (13.10) | 142 (14.20) | 0.194 |
| NSTEMI | 362 (16.45) | 135 (13.45) | 163 (16.30) | 135 (13.50) | ||
| Unstable angina | 1513 (68.74) | 727 (72.41) | 706 (70.60) | 723 (72.30) | ||
| PTCA only | 184 (8.36) | 69 (6.87) | 0.148 | 52 (5.20) | 69 (6.90) | 0.111 |
| Diffuse lesion | 665 (30.21) | 309 (30.78) | 0.748 | 291 (29.10) | 308 (30.80) | 0.407 |
| Occlusion disease | 574 (26.08) | 250 (24.90) | 0.479 | 227 (22.70) | 248 (24.80) | 0.270 |
| Bifurcation disease | 432 (19.63) | 205 (20.42) | 0.603 | 183 (18.30) | 204 (20.40) | 0.235 |
| Diseased vessels | ||||||
| Left main coronary artery | 197 (8.95) | 74 (7.37) | 0.136 | 82 (8.20) | 74 (7.40) | 0.505 |
| Left anterior descending artery | 1706 (77.51) | 775 (77.19) | 0.841 | 786 (78.60) | 772 (77.20) | 0.451 |
| Left circumflex artery | 1275 (57.93) | 553 (55.08) | 0.131 | 562 (56.20) | 551 (55.10) | 0.621 |
| Right coronary artery | 1192 (54.16) | 517 (51.49) | 0.161 | 497 (49.70) | 515 (51.50) | 0.421 |
| Number of diseased vessels | ||||||
| 1 | 749 (34.03) | 374 (37.25) | 0.107 | 359 (35.90) | 373 (37.30) | 0.596 |
| 2 | 806 (36.62) | 367 (36.55) | 387 (38.70) | 365 (36.50) | ||
| 3 | 646 (29.35) | 263 (26.20) | 254 (25.40) | 262 (26.20) | ||
| No. of stents per patient | 1.65 ± 1.11 | 1.56 ± 1.00 | 0.039 | 1.53 ± 0.96 | 1.57 ± 1.00 | 0.337 |
| Ticagralor | 835 (37.94) | 401 (39.94) | 0.280 | 381 (38.10) | 397 (39.70) | 0.463 |
| β-blocker | 1568 (71.24) | 685 (68.23) | 0.083 | 720 (72.00) | 682 (68.20) | 0.063 |
| ACEI/ARB | 913 (41.48) | 383 (38.15) | 0.074 | 410 (41.00) | 383 (38.30) | 0.217 |
| Statins | 2153 (97.82%) | 980 (97.61%) | 0.710 | 977 (97.70) | 978 (97.80) | 0.880 |
[i] Values are n (%) or mean ± SD. BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; MI, myocardial infarction; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; WBC, White blood cell count; STEMI, ST segment–elevation myocardial infarction; NSTEMI, non-ST segment–elevation myocardial infarction; PTCA, Percutaneous transluminal coronary angioplasty; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention.
Table 2
Clinical outcomes at 1-year before and after propensity score matching.
| THE TOTAL STUDY COHORT | THE PROPENSITY-SCORE-MATCHED COHORT | |||||||
|---|---|---|---|---|---|---|---|---|
| DAPT > 1Y (N = 2201) | DAPT = 1Y (N = 1004) | UNADJUSTED HR (95% CI) | P VALUE | DAPT > 1Y (N = 1000) | DAPT = 1Y (N = 1000) | ADJUSTED HR (95% CI) | P VALUE | |
| MACCE | 18 (0.82) | 13 (1.29) | 0.58 (0.27–1.23) | 0.152 | 5 (0.50) | 13 (1.30) | 0.23 (0.05–1.10) | 0.065 |
| All cause death | 7 (0.32) | 7 (0.70) | 0.35 (0.11–1.17) | 0.089 | 2 (0.20) | 7 (0.70) | 0.14 (0.02–1.20) | 0.073 |
| Cardiac death | 4 (0.18) | 2 (0.20) | 0.51 (0.07–3.80) | 0.513 | 2 (0.20) | 2 (0.20) | 0.39 (0.03–4.80) | 0.465 |
| MI | 2 (0.09) | 1 (0.10) | 0.95 (0.09–10.61) | 0.969 | 1 (0.10) | 1 (0.10) | 1.00 (0.06–16.02) | 0.999 |
| Stroke | 9 (0.41) | 5 (0.50) | 0.81 (0.27–2.47) | 0.717 | 2 (0.20) | 5 (0.50) | 0.38 (0.07–2.04) | 0.262 |
| Revascularization | 70 (3.18) | 10 (1.00) | 2.97 (1.52–5.78) | 0.001 | 32 (3.20) | 10 (1.00) | 3.36 (1.64–6.87) | 0.001 |
| Stent thrombosis | 16 (0.72) | 4 (0.39) | 1.80 (0.60–5.42) | 0.294 | 7 (0.69) | 4 (0.40) | 1.88 (0.54–6.51) | 0.317 |
| Bleeding BARC ≥ 2 | 35 (1.59) | 24 (2.39) | 0.70 (0.40–1.20) | 0.195 | 16 (1.60) | 24 (2.40) | 0.63 (0.32–1.24) | 0.179 |
[i] Values are n (%). CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction.
Figure 1
Kaplan-Meier Estimate of outcome events according to DAPT duration. A: Propensity-score-matched cumulative incidence of MACCE during the period from 12 to 18 months according to study group. B: Propensity-score-matched cumulative incidence of significant bleeding events C: Propensity-score-matched cumulative incidence of revascularization; MACCE, major adverse cardiovascular and cerebrovascular events.
Table 3
Subgroup analysis for major adverse cardiovascular and cerebrovascular events during the period from 12 to 24 months in the propensity-score-matched sample.
| DAPT > 1Y (N = 1000) | DAPT = 1Y (N = 1000) | ADJUSTED HR (95% CI) | INTERACTIVE P VALUE | |
|---|---|---|---|---|
| P2Y12 receptor inhibitor | 0.468 | |||
| Clopidogrel | 3/619 (0.48) | 10/603 (1.66) | 0.30 (0.08–1.08) | |
| Ticagrelor | 2/381 (0.52) | 3/397 (0.76) | 0.56 (0.10–3.76) | |
| Age | 0.703 | |||
| >60 | 3/470 (0.64) | 9/456 (1.97) | 0.32 (0.09–1.19) | |
| ≤60 | 2/530 (0.38) | 4/544 (0.74) | 0.47 (0.09–2.59) | |
| Diabetes | 0.833 | |||
| Yes | 1/300 (0.33) | 3/283 (1.06) | 0.41 (0.13–1.31) | |
| No | 4/700 (0.57) | 10/717 (1.39) | 0.31 (0.03–3.00) | |
| Smoke | 0.165 | |||
| Yes | 1/329 (0.30) | 7/320 (2.19) | 0.14 (0.02–1.11) | |
| No | 4/671 (0.60) | 6/680 (0.88) | 0.71 (0.20–2.53) | |
| Renal dysfunction | 0.904 | |||
| Yes | 2/219 (0.91) | 5/220 (2.27) | 0.40 (0.08–2.07) | |
| No | 3/781 (0.38) | 8/780 (1.03) | 0.36 (0.10–1.37) |